



FY25 Market Update

25 August 2025

Disclaimer

FY25 Market Update
25 August 2025



This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It provides general background information about the Company's activities current as at the date of this presentation. This presentation is proprietary to GSS. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without express consent of GSS.

No representation or warranty, express or implied, is or will be made in relation to, and no responsibility or liability (whether for negligence, under statute or otherwise) is or will be accepted by the Company or by any of its officers, directors, shareholders, employees or advisers as to or in relation to the accuracy or completeness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or any omission from this presentation or of any other written or oral information or opinions provided now or in the future to any interested party or its advisers. In particular, no representation or warranty is given as to the achievement or reasonableness of any plans, future projections, management targets, prospects or returns and nothing in this presentation is or should be relied upon as a promise or representation as to the future.

The Company expressly disclaims all liability for any loss or damage of whatsoever kind (whether foreseeable or not) which may arise from any person acting on any information and opinions relating to the Company contained in this presentation or any information which is made available in connection with any further enquiries, notwithstanding any negligence, default or lack of care. In furnishing this presentation, the Company undertakes no obligation to provide any additional information.

Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in these materials to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Company since the date of the presentation.

This presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any or contract or investment decision. This presentation may not be released to US wire services or distributed in the United States. Without limiting the foregoing, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or in other jurisdictions where it would be illegal. The securities of Genetic Signatures have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable US state securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable US state securities laws.

The receipt of this presentation by any person and any information contained herein or subsequently communicated to any person is not to be taken as constituting the giving of investment advice by the Company or any other person to any such person. No such person should expect the Company or any of its officers, directors, shareholders, employees or advisers to owe it any duties or responsibilities and should take its own professional advice. The Recipient must rely solely on its own knowledge, investigation, judgement and assessment of the matters which are the subject of this presentation and to satisfy itself as to the accuracy and completeness.





Who We Are

Genetic Signatures is an Australian ASX-listed molecular diagnostics company, specialising in high-throughput syndromic PCR testing for detecting infectious diseases, helping to diagnose earlier, keeping people healthier.

What We Do

We develop and commercialise rapid, high-throughput PCR tests, powered by our proprietary **3base®** technology that streamlines DNA analysis for faster, more accurate results. We focus on syndromic testing, which is the detection of multiple pathogens that cause similar symptoms in just one single test.

Where Do We Operate

- Headquartered in Sydney, Australia
- Sales and field service teams in Australia, EMEA and United States
- Channel partners in EMEA & Canada



- **Revenue grew 63%** to \$15.9m driven by strong demand (FY24: \$9.8m)
- **Gross margin lifted** to 55% (FY24: 53%)
- **Underlying losses reduced** by 28% to \$12.7m (FY24: \$17.6m)
- Reported **statutory loss** of \$20.1m, including a **\$7.0m impairment expense**
- **Cash reserves of \$30.9m** and **no debt** as of 30 June 2025
- New partnerships with **Tecan Group** and **Repado** to deliver a new automated solution
- **Strategic refocus** to align resources with long-term growth priorities
- **First US commercial contracts signed**, marking a major milestone in global expansion




FY25 Result

25 August 2025



Extended respiratory season in Australia resulting in strong revenue result for the year

- Total revenue for FY25 reached **\$15.9m (\$9.8m FY24)**
- Revenue in the second half of FY25 grew 19.4% year-on-year
- International markets contributed **9.2%** of total sales




Financial Summary – FY25 Profit & Loss

FY25 Market Update
25 August 2025



A'000s	FY25	FY24
Sales revenue	15,900	9,766
Cost of materials	(7,128)	(4,537)
Gross profit	8,772	5,229
Employee benefits expense	(16,066)	(15,139)
Scientific consumables & clinical trials	(2,119)	(3,375)
Other expenses	(6,377)	(6,806)
EBITDA	(15,790)	(20,091)
Depreciation & amortisation	(2,404)	(1,995)
EBIT	(18,194)	(22,086)
Other income	5,464	4,506
Underlying loss	(12,730)	(17,580)
Impairment expenses	(6,996)	-
Restructure expenses	(378)	(282)
Statutory loss	(20,104)	(17,862)

- Sales of \$15.9m during FY25 (FY24: \$9.8m), an improvement of 63%
- Gross margin grew to 55% (FY24: 53%)
- Employee expenses increased by 6% driven by salary adjustments, increased on-costs, and additional hires to support ongoing development and commercialisation efforts
- Continued investment in R&D activities, focused on workflow and assay enhancements
- Maintained a strong balance sheet with \$30.9m in cash and term deposits as at 30 June 2025 and no debt



- Cash and term deposits totaled \$30.9m as at 30 June 2025 (30 June 2024: \$36.3m)
- R&D grant received for \$5.0m for eligible expenditure in FY 24 received during the year
- Cash proceeds of \$8.2m from the retail component of the last capital raise was received in July 2024
- Operating cash outflow \$12.3m, including R&D grant of \$5.0m.

Note: Term deposits treated as a financial asset for accounting purposes at 30 June 2025 but included as cash for illustrative purposes.



Genetic Signatures

Transforming
Molecular
Diagnostics




Operational Update

25 August 2025

Key Achievements in FY25

FY25 Market Update
25 August 2025






- Using **resources** wisely
- Having laser **focus**
- Leading with **simplification**





Objective: align resources with long-term growth priorities

- **Streamlined teams** with a \$380k one-off cost to align talent for future growth
- **Focus on expertise** to strengthen capabilities
- **Positioned for innovation** in next generation instruments and products for long-term commercial success





Faster development timelines



Lower development costs



Enhanced automation

A Well-Considered Strategic Pivot

- Secures the most commercially viable path forward
- \$6.7m impairment charge in FY25



Fresh Market Assessments

- Identified priority syndromic infectious disease areas
- Findings will inform and direct our future focus





Approved products sold in Australia



Respiratory



Viral



Bacterial



Enteric



Viral



Bacterial



Parasite



- **Revenue soared 66% to \$14.4m**, delivering standout year on year growth
- **Strong respiratory sales** powered across all quarters
- **Partnered with leading Australian pathology providers** to scale testing capacity and meet winter demand peaks





Approved products sold in EMEA



Respiratory



Viral



Bacterial



Enteric



Viral



Bacterial



Parasite



- EMEA revenue up 40% to \$1.5m fuelled by surging demand for enteric products and strong regional execution
- Enteric sales focus pays off with 208% year-on-year growth
- NHS trusts in the UK adopt our tests boosting **infection control** and **preventing outbreaks** in high-demand hospital wards
- Streamlined EMEA operations, concentrating resources in core markets





Approved products sold in the US



Respiratory



Viral



Bacterial



Enteric



Viral




Bacterial



Parasite



- **New go-to-market strategy launched**, engaging stakeholders – from patients to payers
- **US operations strengthened** with strategic leadership hires and team changes boost performance
- **Sales pipeline progressing**, with steady advancement
- **First US commercial contracts secured**, marking a pivotal milestone
- **Brand profile raising** for the *EasyScreen*™ Gastrointestinal Parasite Detection Kit and 3base® technology





Power of 3

Every patient is important. Our molecular diagnostic solutions empower healthcare professionals to make informed decisions, improve patient outcomes, and build trust in every treatment journey.

At Genetic Signatures we harness the Power of 3:

- to Discover the unknown,
- Diagnose with precision,
- Treat with confidence.

We are collaborative, courageous, and deliver excellence. We foster a culture of teamwork, innovation and quality, where every challenge is met with bold solutions.

We have the Power of 3. We are Genetic Signatures.



Be Bold

We are curious and challenge assumptions, aim for excellence and dare to make the move.



Be One

We lift each other, challenge fiercely, and win as a team.



Own It

We do what it takes. Every time. We share our wins and own our mistakes.



- **US growth drive:** roll out revised go-to-market strategy to drive engagement with patients, clinicians, payers, labs and hospital administrators into revenue in FY26
- **EMEA momentum:** build on FY25 success to expand market share in signing at least 4 major accounts
- **Australia focus:** retain and grow customer base while increasing revenue. Prepare for upcoming procurement opportunities
- **Performance boost:** optimise on market products for greater efficiency and scalability
- **Innovation pipeline:** progress the development of new automated hardware and software solutions





Contact Us

Allison Rossiter

Chief Executive Officer

E: allison.rossiter@geneticsignatures.com

P: +61 (02) 9870 7580

Karl Pechmann

Chief Financial & Operating Officer &
Joint Company Secretary

E: karl.pechmann@geneticsignatures.com

Visit us

www.geneticsignatures.com

Follow us

